CREB1 and cancer: Collectively, these links between reduced TTP expression and repressed CREB activity in cancer support the idea that therapeutic CREB agonists, for example colforsin, salbutamol, clenbuterol, or isoprenaline, may show benefit as therapeutics for TTP-low expressing tumors, particularly ones where there is a decrease in CREB activity.